Data for "Cognitive enhancer effects of low memantine doses are facilitated by an alpha7 nicotinic acetylcholine receptor agonist in scopolamine-induced amnesia in rats"

For detailed description, refer to the linked article: Bali ZK, Bruszt N, Tadepalli SA, Csurgyók R, Nagy LV, Tompa M, Hernádi I. Cognitive enhancer effects of low memantine doses are facilitated by an alpha7 nicotinic acetylcholine receptor agonist in scopolamine-induced amnesia in rats. Front Pharmacol 2019;10:73. doi: 10.3389/fphar.2019.00073. Short description: Data from spontaneous alternation task of rats in a t-maze. For detailed description of the behavioral protocol, refer to Bali et al. (2015). Adult male Long Evans (LE) and Wistar (W) rats were used. Rats performed a maximum of 15 trials in each sessions (max. 25 min). Rats were acutely treated with different doses of memantine and/or alpha7 nicotinic acetylcholine receptor agonist PHA-543613 (s.c., both). As a model of cognitive impairment, scopolamine-induced transient amnesia was used, thus, scopolamine was administered i.p. in all treatment condition (except of Control, where all pharmacological agents were replaced with physiological saline). Treatments were compared in a within-subject design, order of the sessions (i.e., different treatments) was randomized in a latin-square design. Measured variables: 1) Alternation rate: (No. of correct alternations) / (No. of all trials - 1) 2) Average choice latency: choice latency in a given trial is the time elapsed from opening the door until the entry into one of the goal arms. Data from trials in a given sessions were averaged. 3) Average trial time: trial time in a given trials is the time elapsed from opening the door until returning into the start arm. Data from trials in a given sessions were averaged. Treatments: 1) Control: Average of data in 3-6 habituation and training sessions before pharmacological experiments. Pharmacological agents were replaced by injections of physiological saline. 2) Scop: Scopolamine (0.5 mg/kg, i.p.) alone treatment (reference treatment). Memantine and PHA-543613 injections were replaced by saline. 3) Mem[dose]: Memantine monotreatment. Rats were treated with the given dose of memantine (dose in mg/kg, s.c.) and scopolamine (0.5 mg/kg, i.p.). PHA-543613 was replaced by saline. 4) PHA[dose]: PHA-543613 monotreatment. Rats were treated with the given dose of PHA-543613 (dose in mg/kg, s.c.) and scopolamine (0.5 mg/kg, i.p.). Memantine was replaced by saline. 5) Mem[dose]+PHA[dose]: Combinational treatment. Rats were treated with the given dose of memantine (dose in mg/kg, s.c.), and the given dose of PHA-543613 (dose in mg/kg, s.c.) and scopolamine (0.5 mg/kg, i.p.). Bali, Z.K., Inkeller, J., Csurgyók, R., Bruszt, N., Horváth, H., Hernádi, I., 2015. Differential effects of α7 nicotinic receptor agonist PHA-543613 on spatial memory performance of rats in two distinct pharmacological dementia models. Behav. Brain Res. 278, 404–10. doi:10.1016/j.bbr.2014.10.03